(8S,10S)-10-(4-Amino-5-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxy-acetyl)-1-methoxy-7,8,9,10-tetrahydro-naphthacene-5,12-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: (8S,10S)-10-(4-Amino-5-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxy-acetyl)-1-methoxy-7,8,9,10-tetrahydro-naphthacene-5,12-dione
• 英文别名: doxorubicin；adriamycin；(7S,9S)-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione；(7S,9S)-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• 化学式: C₂₇H₂₉NO₁₁
• 分子量: 543.527
• InChiKey: AOJJSUZBOXZQNB-SNFLSGHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  206
• 氢给体数：
  6
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  二甘醇酸 、 azido-PEG24-CO[N(PN)2][Lys]4[(α-NH2*TFA)(ε-NHPEG1100)]4 、 (8S,10S)-10-(4-Amino-5-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxy-acetyl)-1-methoxy-7,8,9,10-tetrahydro-naphthacene-5,12-dione 生成 azido-PEG₂₄-CO[N(PN)₂][Lys]₄[(α-NH-DGA-3'-NH-dox)(ε-NH-COPEG₁₁₀₀)]₄
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• [EN] PIKFYVE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE PIKFYVE
  申请人：ACURASTEM INCORPORATED

  公开号：WO2021163727A1

  公开（公告）日：2021-08-19

  The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

  本发明涉及作为磷脂酰肌醇-3-磷酸5-激酶（PIKfyve）抑制剂的化合物，以及它们用于治疗与PIKfyve相关的疾病和紊乱的用途。
• [EN] DT-DIAPHORASE-ACTIVE AGENTS FOR TREATMENT OF PEDIATRIC TUMORS<br/>[FR] AGENTS ACTIFS DT-DIAPHORASE POUR LE TRAITEMENT DE TUMEURS PÉDIATRIQUES
  申请人：ALLOS THERAPEUTICS INC

  公开号：WO2009046127A1

  公开（公告）日：2009-04-09

  The present invention is directed to methods for treating patients having a pediatric cancer, comprising administering to a patient an effective amount of the compound 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). The cancer can include Ewing's sarcoma, osteosarcoma, and neuroblastoma, among others. The compound can also be administered together with an effective amount of cisplatin and/or an effective amount of doxorubicin.

  本发明涉及治疗患有儿童癌症的患者的方法，包括向患者施用化合物2,5-二氮杂环丙基-3-(羟甲基)-6-甲基-1,4-苯醌（RH1）的有效量。癌症可以包括尤因氏肉瘤、骨肉瘤和神经母细胞瘤等。该化合物还可以与顺铂的有效量和/或阿霉素的有效量一起施用。
• [EN] T-CELL LYMPHOMA TREATMENTS<br/>[FR] TRAITEMENTS DE LYMPHOME T
  申请人：HOPE CITY

  公开号：WO2018232274A1

  公开（公告）日：2018-12-20

  Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound. Also described herein are pharmaceutical compositions and compositions for use that include such ETP compound.

  本文描述了治疗需要的T细胞淋巴瘤的方法，包括向需要的受试者施用ETP化合物。本文还描述了包含这种ETP化合物的药物组合物和用途组合物。
• [EN] ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS<br/>[FR] COMPOSÉS CIBLANT DES RÉCEPTEURS HORMONAUX NUCLÉAIRES ANTICANCÉREUX
  申请人：NUVATION BIO INC

  公开号：WO2020232119A1

  公开（公告）日：2020-11-19

  The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

  该披露涉及从核类固醇受体结合物中衍生的抗癌化合物，以及含有这些化合物的产品，以及它们的使用和制备方法。